Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
5
|
| pubmed:dateCreated |
1989-11-29
|
| pubmed:abstractText |
Membrane receptors for [D-Trp6]-luteinizing hormone-releasing hormone [( D-Trp6]-LH-RH), somatostatin (SS-14), and epidermal growth factor (EGF) were investigated in experimental N-nitrosobis-(2-oxopropyl)-amine (BOP)-induced pancreatic cancers of hamsters and in specimens of normal human pancreas and human pancreatic cancer obtained from autopsies. Membrane receptors for [D-Trp6]-LH-RH were absent in the pancreas of normal hamsters, but appeared after the carcinoma was induced with BOP. Binding capacity of SS-14 receptors was lower in membranes of BOP-induced pancreatic cancers than in the normal pancreas. In the BOP-induced pancreatic cancers, the receptors were also characterized following in vivo treatment of hamsters with microcapsules of the agonist [D-Trp6]-LH-RH, somatostatin analog RC-160, and the combination of both peptides, which resulted in significant tumor inhibition. Therapy with [D-Trp6]-LH-RH and RC-160, alone or in combination, decreased the binding capacity of receptors for [D-Trp6]-LH-RH, but increased Bmax for SS-14. There were no significant changes in characteristics of the EGF receptor following these therapies. Membranes from human pancreatic cancers showed binding sites for [D-Trp6]-LH-RH, but no binding was detected in normal human pancreas. The presence of receptors for LH-RH in pancreatic tumors of hamster and humans raises the intriguing possibility that LH-RH could be involved in complex interactions that contribute to the appearance of pancreatic cancer. The binding capacity of receptors for SS-14 in human pancreatic cancer membranes was lower, while Bmax for EGF was higher, as compared to normal pancreas.(ABSTRACT TRUNCATED AT 250 WORDS)
|
| pubmed:grant | |
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Carcinogens,
http://linkedlifedata.com/resource/pubmed/chemical/Gonadotropin-Releasing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Luteinizing Hormone,
http://linkedlifedata.com/resource/pubmed/chemical/Nitrosamines,
http://linkedlifedata.com/resource/pubmed/chemical/Receptor, Epidermal Growth Factor,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, LHRH,
http://linkedlifedata.com/resource/pubmed/chemical/Receptors, Somatotropin,
http://linkedlifedata.com/resource/pubmed/chemical/Somatostatin,
http://linkedlifedata.com/resource/pubmed/chemical/Triptorelin Pamoate,
http://linkedlifedata.com/resource/pubmed/chemical/nitrosobis(2-oxopropyl)amine,
http://linkedlifedata.com/resource/pubmed/chemical/vapreotide
|
| pubmed:status |
MEDLINE
|
| pubmed:issn |
0885-3177
|
| pubmed:author | |
| pubmed:issnType |
Print
|
| pubmed:volume |
4
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
521-8
|
| pubmed:dateRevised |
2011-11-17
|
| pubmed:meshHeading |
pubmed-meshheading:2573055-Adenocarcinoma,
pubmed-meshheading:2573055-Animals,
pubmed-meshheading:2573055-Antineoplastic Agents,
pubmed-meshheading:2573055-Autopsy,
pubmed-meshheading:2573055-Carcinogens,
pubmed-meshheading:2573055-Cricetinae,
pubmed-meshheading:2573055-Female,
pubmed-meshheading:2573055-Gonadotropin-Releasing Hormone,
pubmed-meshheading:2573055-Humans,
pubmed-meshheading:2573055-Luteinizing Hormone,
pubmed-meshheading:2573055-Mesocricetus,
pubmed-meshheading:2573055-Nitrosamines,
pubmed-meshheading:2573055-Pancreatic Neoplasms,
pubmed-meshheading:2573055-Receptor, Epidermal Growth Factor,
pubmed-meshheading:2573055-Receptors, LHRH,
pubmed-meshheading:2573055-Receptors, Somatotropin,
pubmed-meshheading:2573055-Somatostatin,
pubmed-meshheading:2573055-Triptorelin Pamoate
|
| pubmed:year |
1989
|
| pubmed:articleTitle |
Membrane receptors for peptides in experimental and human pancreatic cancers.
|
| pubmed:affiliation |
Endocrine, Polypeptide and Cancer Institute, Veterans Administration Medical Center, New Orleans, Louisiana 70146.
|
| pubmed:publicationType |
Journal Article,
Research Support, U.S. Gov't, P.H.S.,
Research Support, U.S. Gov't, Non-P.H.S.
|